Published in N Z Med J on August 12, 2005
Lessons for a national pharmaceuticals strategy in Canada from Australia and New Zealand. Can J Cardiol (2007) 0.81
A qualitative evaluation of general practitioners' perceptions regarding access to medicines in New Zealand. BMJ Open (2012) 0.78
Medicines funding: Value for money is nothing new. BMJ (2007) 0.75
Dihydropyridines, felodipine, and PHARMAC. N Z Med J (2005) 1.58
Extracorporeal Membrane Oxygenation for 2009 Influenza A(H1N1) Acute Respiratory Distress Syndrome. JAMA (2009) 9.47
Scrutinising research ethics committees. BMJ (1988) 5.73
Relative hyperlactatemia and hospital mortality in critically ill patients: a retrospective multi-centre study. Crit Care (2010) 1.77
Stiffness after total knee arthroplasty: prevalence, management and outcomes. Knee (2006) 1.64
Intravenous amino acid therapy for kidney function in critically ill patients: a randomized controlled trial. Intensive Care Med (2015) 1.54
PHARMAC responds on long-acting insulin analogues. N Z Med J (2005) 1.53
Going against the flow: the impact of PHARMAC not funding COX-2 inhibitors for chronic arthritis. N Z Med J (2005) 1.53
Do pharmaceutical score cards give us the answers we seek? N Z Med J (2011) 1.43
Variation in the use of medicines by ethnicity during 2006/07 in New Zealand: a preliminary analysis. N Z Med J (2013) 1.40
An assessment of the efficacy and tolerability of a 'double dose' of normal-release morphine sulphate at bedtime. Palliat Med (2002) 1.40
PHARMAC and tobacco control in New Zealand: two licensed funded options are already available. N Z Med J (2005) 1.40
PHARMAC's response on temozolomide and funding costly medicines that prolong life shortly. N Z Med J (2005) 1.39
Climate science, denial and the Declaration of Delhi. N Z Med J (2009) 1.39
Direct-to-consumer advertising--yes it can compromise patient health. N Z Med J (2003) 1.39
Terminations of pregnancy associated with isotretinoin use in New Zealand. N Z Med J (2011) 1.39
PHARMAC responds to Richard Milne on discounting health benefits and costs. N Z Med J (2005) 1.36
The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood (2002) 1.21
Supportive, palliative, and end-of-life care for patients with cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2012. Lancet Oncol (2012) 1.19
Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer. Eur Radiol (2014) 1.05
Full-feeding with enteral nutrition is not always "full-feeding" in research and clinical practice. JPEN J Parenter Enteral Nutr (2015) 1.05
A community-based exercise programme to improve functional ability in people with Alzheimer's disease: a randomized controlled trial. Scand J Caring Sci (2011) 1.01
Health and equity impacts of climate change in Aotearoa-New Zealand, and health gains from climate action. N Z Med J (2014) 0.99
A randomized double-blind placebo-controlled dose-escalation phase 1 study of aerosolized amikacin and fosfomycin delivered via the PARI investigational eFlow® inline nebulizer system in mechanically ventilated patients. J Aerosol Med Pulm Drug Deliv (2014) 0.98
Early decompressive craniectomy for patients with severe traumatic brain injury and refractory intracranial hypertension--a pilot randomized trial. J Crit Care (2007) 0.98
Delays in discharge in a tertiary care pediatric hospital. J Hosp Med (2009) 0.97
Extracorporeal carbon dioxide removal for patients with acute respiratory failure secondary to the acute respiratory distress syndrome: a systematic review. Crit Care (2014) 0.97
Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study. Eur J Clin Pharmacol (2011) 0.96
Our advice? Get a budget! Healthc Pap (2002) 0.94
Old letters, new rules. Lancet (2003) 0.93
Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood (2013) 0.93
Definitions and outcome measures of clinical trials regarding opioid-induced constipation: a systematic review. J Clin Gastroenterol (2015) 0.92
Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients. Eur J Clin Pharmacol (2010) 0.90
An assessment of aetiology-based guidelines for the management of nausea and vomiting in patients with advanced cancer. Support Care Cancer (2005) 0.90
PHARMAC measures savings elsewhere to the health sector. N Z Med J (2003) 0.89
Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study. J Support Oncol (2011) 0.88
Comparison of the effectiveness of manual and ventilator hyperinflation at different levels of positive end-expiratory pressure in artificially ventilated and intubated intensive care patients. Heart Lung (2006) 0.88
Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment. Br J Haematol (2013) 0.87
Veno-arterial extracorporeal membrane oxygenation for adult cardiovascular failure. Curr Opin Crit Care (2014) 0.87
Opinions of patients with cancer on the relative importance of place of death in the context of a 'good death'. BMJ Support Palliat Care (2011) 0.86
National prescribing data for dabigatran. N Z Med J (2012) 0.85
Implementation of a management guideline aimed at minimizing the severity of primary graft dysfunction after lung transplant. J Thorac Cardiovasc Surg (2009) 0.85
Surveillance investigations after high-dose therapy with stem cell rescue for recurrent follicular lymphoma have no impact on management. Haematologica (2010) 0.84
Response from PHARMAC: difficult choices. N Z Med J (2003) 0.84
Adjudication of bleeding outcomes in an international thromboprophylaxis trial in critical illness. Thromb Res (2013) 0.83
Breakthrough cancer pain: a comparison of surveys with European and Canadian patients. Support Care Cancer (2014) 0.83
More from PHARMAC on long-acting insulin analogues: insulin glargine now funded. N Z Med J (2006) 0.83
A practical approach to clinical lung transplantation from a Maastricht Category III donor with cardiac death. J Heart Lung Transplant (2007) 0.82
Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Celecoxib's relative gastrointestinal safety is overstated. BMJ (2003) 0.81
Assessing the value for money of pharmaceuticals in New Zealand--PHARMAC's approach to cost-utility analysis. N Z Med J (2013) 0.80
End points for phase II trials in intensive care: recommendations from the Australian and New Zealand Clinical Trials Group consensus panel meeting. Crit Care Resusc (2012) 0.80
Guidelines for the management of breakthrough pain in patients with cancer. J Natl Compr Canc Netw (2013) 0.80
Seretide meta-analysis missed important features and overstates any advantages over concurrent LABA/ICS devices. J Allergy Clin Immunol (2004) 0.79
The influence of pulmonary receptors on respiratory drive in a rabbit model of pulmonary emphysema. Respir Physiol Neurobiol (2006) 0.79
PHARMAC responds on tolterodine for overactive bladder. N Z Med J (2005) 0.78
Feasibility and impact of a computer-guided consultation on guideline-based management of COPD in general practice. Prim Care Respir J (2012) 0.78
PHARMAC responds on Herceptin assumptions and decisions. N Z Med J (2007) 0.78
The World Health Organization three-step analgesic ladder comes of age. Palliat Med (2004) 0.78
Is oxycodone efficacy reflected in serum concentrations? A multicenter, cross-sectional study in 456 adult cancer patients. J Pain Symptom Manage (2012) 0.78
A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma. Br J Haematol (2013) 0.77
An evaluation of the activity of a 7-day, nurse-led specialist palliative care service in an acute district general hospital. Int J Palliat Nurs (2013) 0.77
Peptides derived from nucleoside beta-amino acids form an unusual 8-helix. Chem Commun (Camb) (2007) 0.77
Nutritional therapy in acute pancreatitis--time to take stock. Nutrition (2012) 0.76
III. Applying molecular phenotyping in practice. Hematol Oncol (2013) 0.76
PHARMAC responds on salbutamol. N Z Med J (2005) 0.76
PHARMAC responds on long-acting inhalers for COPD. N Z Med J (2005) 0.76
PHARMAC responds to the RMI's editorial. N Z Med J (2005) 0.75
PHARMAC and statins--getting the best population health gains. N Z Med J (2006) 0.75
PHARMAC's response on clopidogrel. N Z Med J (2006) 0.75
PHARMAC and statins--correction is needed. N Z Med J (2007) 0.75
PHARMAC's response on gemcitabine and transparency. N Z Med J (2005) 0.75
PHARMAC and cardiovascular health in New Zealand. N Z Med J (2008) 0.75
PHARMAC responds on agents to prevent osteoporotic fractures. N Z Med J (2006) 0.75
PHARMAC responds on treatments for pulmonary arterial hypertension. N Z Med J (2005) 0.75
More about cardiovascular disease and lipid management in New Zealand. N Z Med J (2002) 0.75
PHARMAC responds on TNF inhibitors for inflammatory arthritis. N Z Med J (2005) 0.75
Testing for Schmallenberg virus. Vet Rec (2013) 0.75
More on PHARMAC and tobacco control in New Zealand. N Z Med J (2006) 0.75
Balancing the risks and benefits of celecoxib. Am J Med (2007) 0.75
Response to 'Exceptional circumstances and heart transplantation' letter. N Z Med J (2005) 0.75
PHARMAC and EpiPen for anaphylaxis. N Z Med J (2006) 0.75
Funding a clinical trial: the perspective of a medicines funder. Pharmacoeconomics (2008) 0.75